Wolfgang Wick

Prof. Dr. Wolfgang Wick is a leading academic in neuro-oncology at Heidelberg University, serving as Medical Director of the Neurology Clinic and Spokesperson for multiple research programs. He holds a professorship in clinical neuro-oncology and leads the Stroke Consortium Rhine-Neckar. His career includes roles at prestigious institutions like Harvard Medical School and the University of Tübingen. Wick specializes in primary brain tumors, neuroimmunology, and translational therapies, with a focus on clinical trials and molecular diagnostics. He has received numerous awards for his contributions to neuro-oncology and holds leadership positions in organizations like the European Cancer Organization (ECCO) and the European Association for Neuro-Oncology (EANO).

• Affiliations: University Hospital Heidelberg (UKHD), NCT Heidelberg, EORTC Brain Tumor Group
• Key Roles: Director of Neurology Clinic, Spokesperson for SFB 1389 UNITE Glioblastoma, Member of NCT Board

His research emphasizes targeted therapies, immunotherapy, and anti-angiogenic treatments for gliomas. Wick coordinates major clinical trials, including studies on CAR-T cells, bevacizumab, and tumor vaccines. He is also involved in advancing neuroimaging and biomarker technologies for diagnosis and prognosis.

Scientific achievements include pioneering work on glioblastoma recurrence mechanisms and molecular profiling of brain tumors. His awards reflect recognition for clinical and translational research excellence.